Trial Profile
Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Doxorubicin; Ethiodized oil; Streptozocin
- Indications Bone metastases; Cancer metastases; Colon cancer; Gastric cancer; Intestinal cancer; Liver metastases; Neuroendocrine tumours; Rectal cancer
- Focus Therapeutic Use
- Acronyms EVACEL; FFCD 1104-EVACEL-GTE
- 27 Mar 2020 Status changed from active, no longer recruiting to completed.
- 31 Oct 2019 Results (n=74) assessing efficacy and tolerability of Everolimus as treatment liver metastases from digestive endocrine tumors post to embolization or chemoembolization, published in the European Journal of Cancer.
- 31 Oct 2019 Primary endpoint (Rate of hepatic progression free survival at 24 months) has not been met as per results published in the European Journal of Cancer.